Lv12
20 积分 2021-02-06 加入
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
6小时前
待确认
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
7小时前
已完结
Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
23小时前
已完结
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
23小时前
已完结
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
23小时前
已完结
乳腺癌CDK4/6抑制剂相关性不良反应管理共识
5个月前
已完结
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
5个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
5个月前
已完结
Global estimates of cancer prevalence for 27 sites in the adult population in 2008
7个月前
已完结
Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence
7个月前
已完结
皖公网安备34019202002308
